安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Ligand Reports First Quarter 2025 Financial Results
On April 17, Ligand announced the signing of a definitive merger agreement to combine Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc and LNHC, Inc (collectively “Pelthos”) with CHRO Merger Sub Inc , a wholly owned subsidiary of Channel Therapeutics
- Ligand Pharmaceuticals - Biopharmas Technology and Capital Partner
Ligand invests in the clinical development and commercialization of high-value medicines We manage one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 90 partnered commercial and development stage programs
- Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International For more information, please visit www ligand com Follow Ligand on X and LinkedIn
- Ligand Pharmaceuticals Incorporated - Investor Relations
Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow We fund the clinical development and commercialization of high-value programs that can improve and extend lives around the world
- Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
Ligand management will host a conference call and webcast today beginning at 8:30 a m Eastern time to discuss this announcement and answer questions “We achieved significant revenue growth in 2024 driven by strong momentum across our major commercial programs,” said Todd Davis, CEO of Ligand
- Team - Ligand Pharmaceuticals
Todd Davis is Chief Executive Officer of Ligand and has served on the company’s Board of Directors since 2007 He has more than 30 years of operational and investment experience and has been involved in more than $4 billion in healthcare financings over his career
- Ligand to Ring the Nasdaq Opening Bell on May 19, 2025
JUPITER, Fla , May 14, 2025 (GLOBE NEWSWIRE) - Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025
- Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs Ligand’s NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications
|
|
|